Gilead Sciences, Inc. $GILD Stock Holdings Lifted by Potomac Fund Management Inc. ADV

Potomac Fund Management Inc. ADV raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,456 shares of the biopharmaceutical company’s stock after purchasing an additional 1,102 shares during the quarter. Gilead Sciences makes up approximately 2.2% of Potomac Fund Management Inc. ADV’s holdings, making the stock its 4th biggest position. Potomac Fund Management Inc. ADV’s holdings in Gilead Sciences were worth $2,134,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GILD. Smallwood Wealth Investment Management LLC purchased a new position in Gilead Sciences in the first quarter valued at about $25,000. Goodman Advisory Group LLC purchased a new position in Gilead Sciences in the first quarter valued at about $29,000. Colonial Trust Advisors grew its stake in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 213 shares in the last quarter. Core Alternative Capital grew its stake in Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 241 shares in the last quarter. Finally, IMA Advisory Services Inc. purchased a new position in Gilead Sciences in the first quarter valued at about $39,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD opened at $114.77 on Monday. Gilead Sciences, Inc. has a twelve month low of $75.91 and a twelve month high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock has a market capitalization of $142.41 billion, a PE ratio of 22.86, a P/E/G ratio of 0.70 and a beta of 0.33. The stock has a 50-day simple moving average of $112.51 and a 200 day simple moving average of $109.16.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same quarter in the previous year, the firm earned $2.01 EPS. The firm’s revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences’s payout ratio is currently 62.95%.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price on the stock in a research note on Tuesday, August 19th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target for the company in a research note on Friday, July 25th. UBS Group increased their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Finally, Royal Bank Of Canada increased their price objective on Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a report on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $115.39.

Insiders Place Their Bets

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the completion of the transaction, the chief executive officer owned 605,725 shares of the company’s stock, valued at approximately $69,016,306.50. The trade was a 1.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at $13,532,333.04. This represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock worth $9,339,230 over the last quarter. 0.27% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.